Monoclonal antibodies Recombinant antibodies

This video discusses the EUA- emergency use authorization granted for monoclonal antibodies to treat mild-to-moderate COVID-19 for non- hospitalized patients at risk for progression to severe disease or hospitalization. The difference in production of the original monoclonal antibodies and the newer recombinant antibodies developed to treat COVID-19 is discussed, as well as the indications and the administration of the various products. Viewers will get a rundown on the authorizations, some contraindications and advantages of these new therapies. The video explains how they work in COVID-19 and ventures to suggest which product should work in the Omicron variant. The production of monoclonal antibodies is explained simply with the help of clear diagrams. Some of the adverse reactions of these therapies are listed so that patients are aware of the potential adverse side effects. The difficulty of the emergence of resistant strains of the SARS-CoV-2 coronavirus is mentioned and which of the products were adversely affected by the emergence of these variants. The viewer should have a better understanding of the use of monoclonal antibodies in covid-19 and should be comfortable discussing the need for this therapy with their physician after viewing his video.